Skip to content

Efficacy of TECAR Therapy in Patients With Knee Osteoarthritis

Evaluation of The Efficacy of TECAR Therapy in Patients With Knee Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06418360
Enrollment
54
Registered
2024-05-17
Start date
2023-03-13
Completion date
2023-11-23
Last updated
2024-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Energy Transfer Capacitative and Resistive Therapy, Knee Osteoarthritis

Keywords

knee pain, osteoarthritis, capacitative and resistive energy transfer therap

Brief summary

Objective: The aim of the present study was to investigate the treatment efficacy of TECAR therapy, a modern application that has been increasingly used in recent years, compared to conventional physical therapy applications in the treatment of knee osteoarthritis, according to the evaluation of the clinical findings of patients. Methods: A total of 54 patients, aged between 40 and 75 years, were randomly divided into two groups. Both groups received CPT. Group 2 received TECAR therapy in addition to CPT, applied three times a week for two weeks, for a total of 6 sessions. All patient's knee joint range of motion (ROM) was measured goniometrically, isometric quadriceps muscle strength was measured, and pain levels were assessed using the Visual Analog Scale (VAS), and disability levels were assessed using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) before treatment, at the end of treatment, at 1 month, and at 3 months.

Interventions

DEVICETECAR

Transfer Energy Capacitative and Resistive Therapy

DEVICEconventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack

10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency

Sponsors

Ankara City Hospital Bilkent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 3 months of conservative treatment for unresponsive knee pain * Kellgren-Lawrence grade 2-3 on radiographic evaluation * Agreed to participate in the study.

Exclusion criteria

* History of physical therapy (electrotherapy/exercise) in the past 3 months * Intra-articular injection therapy in the past 3 months, * History of surgery or trauma to the affected knee * Inflammatory or neurological disease affecting the lower extremities * Active vasculitis or severe peripheral vascular disease * Pregnancy or lactation * Diagnosed restless legs syndrome * Neoplasia * Local sensory impairment, * Local or systemic acute infections * Severe osteoporosis * Pacemaker * Psychiatric disorder and cognitive impairment.

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale (VAS)Before and the after treatment 0th day , 1th month, 3rd month0 min , 10 is maximum pain score
Western Ontario and McMaster Universities Arthritis Index (WOMAC)Before and the after treatment 0th day, 1th month, 3rd monthThis 24-item index comprises three subscales: pain, stiffness, and physical function, each measured on a five-point Likert scale ranging from none to extreme.
Range of Motion (ROM)Before and the after treatment 0th day, 1th month, 3rd monthFlexion and extension of the knee joint were measured using a universal goniometer relative to reference points.

Secondary

MeasureTime frameDescription
The Diers Myoline Isometric Muscle Strength Measurement SystemBefore and the end of treatment 0th day, 1th month, 3rd monthquadriceps muscle Isometric Strength Measure: Increased isometric muscle strength is an indicator of recovery.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026